


<p>PTO-1449 REPRODUCED</p> <p>O I P INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p> <p>June 1, 2004</p> <p>(Use several sheets if necessary)</p>	ATTORNEY DOCKET NO.	APPLICATION NO.
	3033.1008-008	10/766,752
	FIRST NAMED INVENTOR	FILING DATE
	Darrell H. Carney	January 27, 2004
EXAMINER	CONFIRMATION NO.	GROUP
Not Assigned	2963	1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER <u>Robert M</u>	DATE CONSIDERED <u>04-04-05</u>
-----------------------------	------------------------------------


PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 3033.1008-008	CONTINUATION APPLICATION OF NO. PCT/US02/01151	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			FIRST NAMED INVENTOR Darrell H. Carney		FILING DATE
January 27, 2004 (Use several sheets if necessary)			EXAMINER	CONFIRMATION NO.	GROUP

U.S. PATENT DOCUMENTS					
EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	
RM	AA	5,352,664	10-04-1994	Carney <i>et al.</i>	
RM	AB	5,500,412	03-19-1996	Carney <i>et al.</i>	
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				
	AA2				
	AB2				
	AC2				
	AD2				
	AE2				
	AF2				
	AG2				
	AH2				
	AJ2				
	AJ2				
	AK2				
	AA3				
	AB3				
	AC3				

EXAMINER 	DATE CONSIDERED 01-04-05
---	-----------------------------


PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION January 27, 2004 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 3033.1008-008	CONTINUATION APPLICATION OF NO. PCT/US02/01151	
		FIRST NAMED INVENTOR Darrell H. Carney	FILING DATE	
		EXAMINER	CONFIRMATION NO.	GROUP

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
RR	AL	WO 01/49309 A2	07-12-2001	Pfizer Limited	
RR	AM	WO 88/03151	05-05-1988	Board of Regents, The University of Texas System	
	AN				
	AO				
	AP				
	AQ				
	AL2				
	AM2				
	AN2				
	AO2				
	AP2				
	AQ2				
	AL3				
	AM3				
	AN3				
	AO3				
	AP3				
	AQ3				
	AL4				
	AM4				
	AN4				
	AO4				
	AP4				
	AQ4				

EXAMINER 	DATE CONSIDERED 04-04-05
---	-----------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION January 27, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3033.1008-008	CONTINUATION APPLICATION OF NO. PCT/US02/01151
	FIRST NAMED INVENTOR Darrell H. Carney	
	EXAMINER	CONFIRMATION NO.
		GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AR	Stiernberg, J., <i>et al.</i> , "Acceleration of full-thickness wound healing in normal rats by the synthetic thrombin peptide, TP508," <i>Wound Repair and Regeneration</i> , 8(3):204-215 (2000).	
AS	Norfleet, A.M., <i>et al.</i> , "Thrombin peptide, TP508, stimulates angiogenic responses in animal models of dermal wound healing, in chick chorioallantoic membranes, and in cultured human aortic and microvascular endothelial cells," <i>General Pharmacology</i> , 35:249-254 (2002).	
AT	Norfleet, A.M., <i>et al.</i> , "Thrombin peptide TP508 accelerates closure of dermal excisions in animal tissue with surgically induced ischemia," <i>Wound Repair and Regeneration</i> , 8(6):517-529 (2000).	
AU	Pernia, S.D., <i>et al.</i> , "A Synthetic Peptide Representing the Thrombin Receptor-Binding Domain Enhances Wound Closure <i>In Vivo</i> ," <i>SAAS Bulletin: Biochem. & Biotech.</i> , 3:8-12 (1990).	
AV	Carney, Darrell H., "Postclotting Cellular Effects of Thrombin Mediated by Interaction with High-Affinity Thrombin Receptors," In <i>Thrombin Structure and Function</i> , Berliner, L.J. (ed.) (New York: Plenum Press), pp. 351-396 (1992).	
AW	Stiernberg, J., <i>et al.</i> , "The Role of Thrombin and Thrombin Receptor Activating Peptide (TRAP-508) in Initiation of Tissue Repair," <i>Thrombosis and Haemostasis</i> , 70(1):158-162 (1993).	
AX	Carney, D.H., <i>et al.</i> , "Enhancement of Incisional Wound Healing and Neovascularization in Normal Rats by Thrombin and Synthetic Thrombin Receptor-activating Peptides," <i>J. Clin. Invest.</i> , 89:1469-1477 (1992).	
AY	Carney, D.H., <i>et al.</i> , "Role of High-Affinity Thrombin Receptors in Postclotting Cellular Effects of Thrombin," <i>Seminars in Thrombosis and Hemostasis</i> , 18(1):91-102 (1992).	
AZ	Glenn, K.C., <i>et al.</i> , "Synthetic Peptides Bind to High-Affinity Thrombin Receptors and Modulate Thrombin Mitogenesis," <i>Peptide Research</i> , 1(2):65-73 (1988).	
AR2	Sower, L.E., <i>et al.</i> , "Thrombin Peptide, TP508, Induces Differential Gene Expression in Fibroblasts through a Nonproteolytic Activation Pathway," <i>Experimental Cell Research</i> , 247:422-431 (1999).	
AS2	Steed, D.L., <i>et al.</i> , "Promotion and Acceleration of Diabetic Ulcer Healing by Arginine-Glycine-Aspartic Acid (RGD) Peptide Matrix," <i>Diabetes Care</i> , 18(1):39-46 (1995).	

EXAMINER 	DATE CONSIDERED 04-04-05
---	-----------------------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3033.1008-008	APPLICATION NO. 10/766,752
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION February 28, 2005 MAR 02 2005 Use several sheets if necessary)		FIRST NAMED INVENTOR Darrell H. Carney	FILING DATE January 27, 2004
		EXAMINER Mondesi, Robert B.	CONFIRMATION NO. 2963
			GROUP 1653

SEARCHED *O P E* TRADEMARK OFFICE
SEARCHED *PTO* TRADEMARK OFFICE
SEARCHED *PTO* TRADEMARK OFFICE

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
<i>RR</i>	AN	WO 96/40033	12/19/1996	Clarion Pharmaceuticals, Inc.	

SEARCHED *PTO* TRADEMARK OFFICE
SEARCHED *PTO* TRADEMARK OFFICE
SEARCHED *PTO* TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
<i>RP</i>	AV2	Hollenberg, Morley D., et al., "Synergistic Actions of a Thrombin-Derived Synthetic Peptide and a Thrombin Receptor-Activating Peptide in Stimulating Fibroblast Mitogenesis," <i>J. Cell Physiol.</i> 169:491-496 (1996).

EXAMINER <i>Robert B. Mondesi</i>	DATE CONSIDERED 04-04-05
--------------------------------------	-----------------------------